Effectiveness of the BNT162b2 mRNA COVID-19 vaccine among adolescents with juvenile-onset inflammatory rheumatic diseases
Open Access
- 3 August 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 62 (SI2) , SI145-SI151
Abstract
The effectiveness of the BNT162b2 mRNA COVID-19 vaccine for adolescents with juvenile-onset inflammatory or immune rheumatic diseases (IRDs) is unknown. Several studies have suggested attenuated immunogenicity in patients with IRD. This study evaluated the effectiveness of the BNT162b2 mRNA COVID-19 vaccine in preventing COVID-19 infection in adolescents with juvenile-onset IRD compared with controls without immune rheumatic disease. We used data from Clalit Health Services, the largest health-care organization in Israel, to conduct an observational cohort study from February to December 2021, involving 12–18 year-old adolescents diagnosed with IRD. Study outcomes included documented COVID-19 infection in relation to vaccination status and immunomodulatory therapy. We estimated vaccine effectiveness as one minus the risk ratio. Adolescents aged 12–18 years without immune rheumatic disease served as controls. A total of 1639 adolescents with IRD (juvenile idiopathic arthritis, SLE, or familial Mediterranean fever) were included and compared with 524 471 adolescents in the same age range without IRD. There was no difference in COVID-19 infection rates after the second dose of vaccine between those with IRD and controls (2.1% vs 2.1% respectively, P = 0.99). The estimated vaccine effectiveness for adolescents with IRD was 76.3% after the first dose, 94.8% after the second and 99.2% after the third dose. We found that the BNT162b2 mRNA vaccine was similarly effective against COVID-19 infection in adolescents with and without IRD. Immunomodulatory therapy did not affect its effectiveness. These results can encourage adolescents with IRD to get vaccinated against COVID-19.Keywords
This publication has 29 references indexed in Scilit:
- COVID-19 in children: the link in the transmission chainThe Lancet Infectious Diseases, 2020
- Live attenuated MMR/V booster vaccines in children with rheumatic diseases on immunosuppressive therapy are safe: Multicenter, retrospective data collectionVaccine, 2020
- Immunogenicity of sequential 13-valent conjugated and 23-valent unconjugated pneumococcal vaccines in a population of children with lupusLupus, 2018
- The safety of live-attenuated vaccines in patients using IL-1 or IL-6 blockade: an international surveyPediatric Rheumatology, 2018
- Varicella-zoster-virus vaccination in immunosuppressed children with rheumatic diseases using a pre-vaccination check listPediatric Rheumatology, 2018
- Risk of Serious Infection in Juvenile Idiopathic Arthritis Patients Associated With Tumor Necrosis Factor Inhibitors and Disease Activity in the German Biologics in Pediatric Rheumatology RegistryArthritis Care & Research, 2017
- Efficacy, effectiveness, immunogenicity - are not the same in vaccinologyWorld Journal of Gastroenterology, 2013
- Differences in persistence of measles, mumps, rubella, diphtheria and tetanus antibodies between children with rheumatic disease and healthy controls: a retrospective cross-sectional studyAnnals of the Rheumatic Diseases, 2012
- Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatmentArthritis & Rheumatism, 2012
- EULAR recommendations for vaccination in paediatric patients with rheumatic diseasesAnnals of the Rheumatic Diseases, 2011